Alkaline phosphatase isoenzymes in dialysis bone disease.

Mountokalakis, T.; Virvidakis, C.E.; Nicolaou, Anna; Manousos, O. N.

doi:10.1136/bmj.1.6077.1663-a

BMJ

1977

DOI: 10.1136/bmj.1.6077.1663-a

|View full text |Cite

Alkaline phosphatase isoenzymes in dialysis bone disease.

T. Mountokalakis¹,

C.E. Virvidakis²,

Anna Nicolaou³

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

1982

2008

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

(1 citation statement)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…6 Incrementally higher levels of serum AlkPhos can be seen with worsening magnitude of bone turnover. 8,9 We recently showed that surrogates of CKD-MBD, including higher serum levels of minerals and higher AlkPhos levels, were associated with increased all-cause death risk in a 2-yr cohort of 58,000 MHD patients. 2 A recent meta-analysis showed that a decline in serum AlkPhos, not PTH, was the most consistent result of the active vitamin D administration in patients with CKD.…”

mentioning

confidence: 99%

Serum Alkaline Phosphatase Predicts Mortality among Maintenance Hemodialysis Patients

Regidor

Kövesdy

Mehrotra³

et al. 2008

Journal of the American Society of Nephrology

220

222

View full text Add to dashboard Cite

Several observational studies have demonstrated that serum levels of minerals and parathyroid hormone (PTH) have U-or J-shaped associations with mortality in maintenance hemodialysis patients, but the relationship between serum alkaline phosphatase (AlkPhos) and risk for all-cause or cardiovascular death is unknown. In this study, a 3-yr cohort of 73,960 hemodialysis patients in DaVita outpatient dialysis were studied, and the hazard ratios for all-cause and cardiovascular death were higher across 20-U/L increments of AlkPhos, including within the various strata of intact PTH and serum aspartate aminotransferase. In the fully adjusted model, which accounted for demographics, comorbidity, surrogates of malnutrition and inflammation, minerals, PTH, and aspartate aminotransferase, AlkPhos Ն120 U/L was associated with a hazard ratio for death of 1.25 (95% confidence interval 1.21 to 1.29; P Ͻ 0.001). This association remained among diverse subgroups of hemodialysis patients, including those positive for hepatitis C antibody. A rise in AlkPhos by 10 U/L during the first 6 mo was incrementally associated with increased risk for death during the subsequent 2.5 yr. In summary, high levels of serum AlkPhos, especially Ͼ120 U/L, are associated with mortality among hemodialysis patients. Prospective controlled trials will be necessary to test whether serum AlkPhos measurements could be used to improve the management of renal osteodystrophy. 19: 219319: -220319: , 200819: . doi: 10.1681 In advanced chronic kidney disease (CKD; stages 3 through 5), secondary hyperparathyroidism (SHPT), along with renal osteodystrophy, is common and may be associated with abnormal mineral metabolism and/or abnormal serum or tissue mineral levels, vascular calcifications, and poor survival, espe- contributed to the study design and manuscript preparation and reviewed and approved the final manuscript. J Am Soc Nephrol

show abstract

mentioning

confidence: 99%

Serum Alkaline Phosphatase Predicts Mortality among Maintenance Hemodialysis Patients

Regidor

Kövesdy

Mehrotra³

et al. 2008

Journal of the American Society of Nephrology

220

222

View full text Add to dashboard Cite

show abstract

Transitory ultrastructural abnormalities of cilia

Rutland

Cox

Dewar

et al. 1982

British Journal of Diseases of the Chest

View full text Add to dashboard Cite

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Alkaline phosphatase isoenzymes in dialysis bone disease.

Cited by 2 publications

References 1 publication

Serum Alkaline Phosphatase Predicts Mortality among Maintenance Hemodialysis Patients

Serum Alkaline Phosphatase Predicts Mortality among Maintenance Hemodialysis Patients

Transitory ultrastructural abnormalities of cilia

Contact Info

Product

Resources

About